The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
The mode of action of thiazolidinediones
Abstract
The thiazolidinediones (TZDs) or 'glitazones' are a new class of oral antidiabetic drugs that improve metabolic control in patients with type 2 diabetes through the improvement of insulin sensitivity. TZDs exert their antidiabetic effects through a mechanism that involves activation of the gamma isoform of the peroxisome proliferator-activated receptor (PPAR gamma), a nuclear receptor. TZD-induced activation of PPAR gamma alters the transcription of several genes involved in glucose and lipid metabolism and energy balance, including those that code for lipoprotein lipase, fatty acid transporter protein, adipocyte fatty acid binding protein, fatty acyl-CoA synthase, malic enzyme, glucokinase and the GLUT4 glucose transporter. TZDs reduce insulin resistance in adipose tissue, muscle and the liver. However, PPAR gamma is predominantly expressed in adipose tissue. It is possible that the effect of TZDs on insulin resistance in muscle and liver is promoted via endocrine signalling from adipocytes. Potential signalling factors include free fatty acids (FFA) (well-known mediators of insulin resistance linked to obesity) or adipocyte-derived tumour necrosis factor-alpha (TNF-alpha), which is overexpressed in obesity and insulin resistance. Although there are still many unknowns about the mechanism of action of TZDs in type 2 diabetes, it is clear that these agents have the potential to benefit the full 'insulin resistance syndrome' associated with the disease. Therefore, TZDs may also have potential benefits on the secondary complications of type 2 diabetes, such as cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM
Boden, G. (1997) · Diabetes · doi:10.2337/diab.46.1.3 · Cited by 1,728
Molecular Regulation of Adipogenesis
Rosen, E. D., & Spiegelman, B. M. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.145 · Cited by 1,285
Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link
Hotamisligil, G. S., & Spiegelman, B. M. (1994) · Diabetes · doi:10.2337/diab.43.11.1271 · Cited by 1,281
Chawla, A., Schwarz, E. J., Dimaculangan, D. D., & Lazar, M. A. (1994) · Endocrinology · doi:10.1210/en.135.2.798 · Cited by 873
Lemberger, T., Desvergne, B., & Wahli, W. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.335 · Cited by 712
Shyng, S.-L., Lehmann, S., Moulder, K. L., & Harris, D. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.30221 · Cited by 704
Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., & Vidal, H. (1997) · Diabetes · doi:10.2337/diab.46.8.1319 · Cited by 697
Hu, E., Tontonoz, P., & Spiegelman, B. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9856 · Cited by 656
Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 629
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
Mukherjee, R., Davies, P. J. A., Crombie, D. L., Bischoff, E. D., Cesario, R. M., Jow, L., Hamann, L. G., Boehm, M. F., Mondon, C. E., Nadzan, A. M., et al. (1997) · Nature · doi:10.1038/386407a0 · Cited by 605
Mortality and survival in Type 2 (non-insulin-dependent) diabetes mellitus
Panzram, G. (1987) · Diabetologia · doi:10.1007/bf00274216 · Cited by 541
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.280 · Cited by 518
Adams, M., Montague, C. T., Prins, J. B., Holder, J. C., Smith, S. A., Sanders, L., Digby, J. E., Sewter, C. P., Lazar, M. A., Chatterjee, V. K., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119870 · Cited by 517
Peroxisome proliterator-activated receptors, orphans with ligands and functions
Schoonjans, K., Martin, G., Staels, B., & Auwerx, J. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00006 · Cited by 489
Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., & Horikoshi, H. (1988) · Diabetes · doi:10.2337/diab.37.11.1549 · Cited by 473
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells
Law, R. E., Goetze, S., Xi, X.-P., Jackson, S., Kawano, Y., Demer, L., Fishbein, M. C., Meehan, W. P., & Hsueh, W. A. (2000) · Circulation · doi:10.1161/01.cir.101.11.1311 · Cited by 442
Thiazolidinediones: a new class of antidiabetic drugs
Day, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00023.x · Cited by 436
Berger, J., Bailey, P., Biswas, C., Cullinan, C. A., Doebber, T. W., Hayes, N. S., Saperstein, R., Smith, R. G., & Leibowitz, M. D. (1996) · Endocrinology · doi:10.1210/endo.137.10.8828476 · Cited by 391
Wu, Z., Xie, Y., Morrison, R. F., Bucher, N. L., & Farmer, S. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1244 · Cited by 357
Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O., & Reitman, M. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11245 · Cited by 356
Troglitazone action is independent of adipose tissue.
Burant, C. F., Sreenan, S., Hirano, K., Tai, T. A., Lohmiller, J., Lukens, J., Davidson, N. O., Ross, S., & Graves, R. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119839 · Cited by 334
Chen, Z., Ishibashi, S., Perrey, S., Osuga, J.-I., Gotoda, T., Kitamine, T., Tamura, Y., Okazaki, H., Yahagi, N., Iizuka, Y., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.3.372 · Cited by 320
Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling.
Peraldi, P., Xu, M., & Spiegelman, B. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119715 · Cited by 314
Phillips, L. S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E. B., Salzman, A., & the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.2.308 · Cited by 302
Fujita, T., Sugiyama, Y., Taketomi, S., Sohda, T., Kawamatsu, Y., Iwatsuka, H., & Suzuoki, Z. (1983) · Diabetes · doi:10.2337/diab.32.9.804 · Cited by 286
Enhancement of adipocyte differentiation by an insulin-sensitizing agent.
Kletzien, R. F., Clarke, S. D., & Ulrich, R. G. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08890-x · Cited by 284
Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
OGIHARA, T., RAKUGI, H., IKEGAMI, H., MIKAMI, H., & MASUO, K. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)96214-5 · Cited by 274
Insulin Resistance Implications for Type II Diabetes Mellitus and Coronary Heart Disease
Haffner, S. M., & Miettinen, H. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00027-2 · Cited by 229
Young, P. W., Buckle, D. R., Cantello, B. C. C., Chapman, H., Clapham, J. C., Coyle, P. J., Haigh, D., Hindley, R. M., Holder, J. C., Kallender, H., et al. (1998) · PubMed · Cited by 229
Oakes, N. D., Kennedy, C. J., Jenkins, A. B., Laybutt, D. R., Chisholm, D. J., & Kraegen, E. W. (1994) · Diabetes · doi:10.2337/diab.43.10.1203 · Cited by 223
Szalkowski, D. (1995) · Endocrinology · doi:10.1210/en.136.4.1474 · Cited by 176
Loviscach, M., Rehman, N., Carter, L., Mudaliar, S., Mohadeen, P., Ciaraldi, T. P., Veerkamp, J. H., & Henry, R. R. (2000) · Diabetologia · doi:10.1007/s001250050048 · Cited by 176
Souza, S. C., Yamamoto, M. T., Franciosa, M. D., Lien, P., & Greenberg, A. S. (1998) · Diabetes · doi:10.2337/diabetes.47.4.691 · Cited by 166
In vitro studies on the action of CS-045, a new antidiabetic agent
Ciaraldi, T. P., Gilmore, A., Olefsky, J. M., Goldberg, M., & Heidenreich, K. A. (1990) · Metabolism · doi:10.1016/0026-0495(90)90166-a · Cited by 164
Zomer, A. W. M., van der Burg, B., Jansen, G. A., Wanders, R. J. A., Poll‐The, B. T., & van der Saag, P. T. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31973-8 · Cited by 161
Young, P. W., Cawthorne, M. A., Coyle, P. J., Holder, J. C., Holman, G. D., Kozka, I. J., Kirkham, D. M., Lister, C. A., & Smith, S. A. (1995) · Diabetes · doi:10.2337/diab.44.9.1087 · Cited by 146
Fulgencio, J.-P., Kohl, C., Girard, J. R., & Pégorier, J. P. (1996) · Diabetes · doi:10.2337/diab.45.11.1556 · Cited by 129
Oakes, N. D., Camilleri, S., Furler, S. M., Chisholm, D. J., & Kraegen, E. W. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90083-4 · Cited by 121
Ohsumi, J., Sakakibara, S., Yamaguchi, J., Miyadai, K., Yoshioka, S., Fujiwara, T., Horikoshi, H., & Serizawa, N. (1994) · Endocrinology · doi:10.1210/endo.135.5.7956951 · Cited by 111
Park, K. S., Ciaraldi, T. P., Lindgren, K., Abrams-Carter, L., Mudaliar, S. R. D., Nikoulina, S. E., Tufari, S. R., Veerkamp, J. H., Vidal‐Puig, A., & Henry, R. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5034 · Cited by 103
Birgel, M., Gottschling-Zeller, H., Röhrig, K., & Hauner, H. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.6.1682 · Cited by 102
Self-citationMechanisms by which Thiazolidinediones Enhance Insulin Action
Reginato, M. J., & Lazar, M. A. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00110-6 · Cited by 96
Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat
Smith, S. A., Lister, C. A., Toseland, C. D. N., & Buckingham, R. E. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00099.x · Cited by 88
Kruszynska, Y. T., Mukherjee, R., Jow, L., Dana, S. L., Paterniti, J. R., & Olefsky, J. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1076 · Cited by 82
Park, K. S., Ciaraldi, T. P., Abrams-Carter, L., Mudaliar, S. R. D., Nikoulina, S. E., & Henry, R. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4764 · Cited by 72
Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes
Bähr, M., Spelleken, M., Bock, M., von Holtey, M., Kiehn, R., & Eckel, J. (1996) · Diabetologia · doi:10.1007/s001250050509 · Cited by 70
Preadipocyte differentiation in vitro: Identification of a highly active adipogenic agent
Hiragun, A., Sato, M., & Mitsui, H. (1988) · Journal of Cellular Physiology · doi:10.1002/jcp.1041340115 · Cited by 60
Hube, F., & Hauner, H. (2000) · Endocrinology · doi:10.1210/endo.141.7.7561 · Cited by 48
Self-citationKatsuki, A., Sumida, Y., Murata, K., Furuta, M., Araki-Sasaki, R., Tsuchihashi, K., Hori, Y., Yano, Y., Gabazza, E. C., & Adachi, Y. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00072.x · Cited by 43
Gottschling-Zeller, H., Röhrig, K., & Hauner, H. (2000) · Diabetologia · doi:10.1007/s001250050057 · Cited by 41
Self-citation
Cited by
Adipose Tissue-Derived Factors: Impact on Health and Disease
Trujillo, M. E., & Scherer, P. E. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0033 · Cited by 619
Human fat cell lipolysis: biochemistry, regulation and clinical role.
Arner, P. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.07.004 · Cited by 401
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Lagathu, C., Bastard, J.-P., Auclair, M., Maachi, M., Capeau, J., & Caron, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.013 · Cited by 385
Disorders of glucose metabolism in sleep apnea
Punjabi, N. M., & Polotsky, V. Y. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00695.2005 · Cited by 375
Metadata
- Authors
- Hauner, H.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2002
- Volume
- 18
- Issue
- S2
- Pages
- S10-S15
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2168023849
- Cited by
- 411
- References
- 59
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.